Cost‐Effectiveness of Sequential Teriparatide/Alendronate Versus Alendronate‐Alone Strategies in High‐Risk Osteoporotic Women in the US: Analyzing the Impact of Generic/Biosimilar Teriparatide

Teriparatide, currently only available in brand form in the United States, is a costly drug approved for the treatment of postmenopausal osteoporotic women who are at high risk of fracture. Because market exclusivity for brand teriparatide expired in August 2019 in the US, we sought to understand th...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:JBMR Plus
Main Authors: Mori, Takahiro, Crandall, Carolyn J, Ganz, David A
Format: Artigo
Sprog:Inglês
Udgivet: John Wiley & Sons, Inc. 2019
Fag:
Original Articles
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6874180/
https://ncbi.nlm.nih.gov/pubmed/31768491
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jbm4.10233
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker